Quarterly ResultAug 4, 2026, 04:16 PM
OrthoPediatrics Q2 Revenue $70.5M, Raises 2026 Guidance
AI Summary
OrthoPediatrics Corp. reported record second quarter 2026 financial results, with total revenue increasing 15% year-over-year to $70.5 million. The company achieved record adjusted EBITDA of $6.8 million and significantly reduced free cash flow usage by 78%. Following this strong performance, OrthoPediatrics raised its full-year 2026 revenue guidance to a range of $265.0 million to $269.0 million. Additionally, the company announced an exclusive distribution agreement with OSSIO, Inc. for a bio-integrative, metal-free fixation technology.
Key Highlights
- Q2 2026 total revenue reached a record $70.5 million, a 15% increase year-over-year.
- Q2 2026 adjusted EBITDA was $6.8 million, up from $4.1 million in Q2 2025.
- Q2 2026 free cash flow usage improved by 78% to $3.1 million.
- Full-year 2026 revenue guidance increased to $265.0 million - $269.0 million.
- Worldwide Trauma & Deformity revenue grew 26% in Q2 2026 to $52.6 million.
- Q2 2026 net loss was $7.2 million, or $0.30 per basic and diluted share.
- Announced an exclusive distribution agreement with OSSIO, Inc. for metal-free fixation technology.
Price Impact
More from KIDS